Drug susceptibility, defined by the minimal inhibitory concentration (MIC), often does not 25 predict whether fungal infections will respond to therapy in the clinic. Tolerance at supra-MIC 26 antifungal drug concentrations is rarely quantified and current clinical recommendations suggest 27 it be ignored. Here, we measured and characterized drug-response variables that could 28 influence the outcomes of fungal infections and be generalizable across major clades of 29 Candida albicans, one of the most frequently isolated human fungal pathogens. We quantified 30 antifungal tolerance as the fraction of growth (FoG) above the MIC and found that it is clearly 31 distinct from susceptibility/resistance measured as MIC. Instead, tolerance is due to the slow 32 growth of subpopulations of cells that overcome drug stress more efficiently than the rest of the 33 population, and correlates inversely with the accumulation of intracellular drug. Importantly, 34 many adjuvant drugs used together with fluconazole, a fungistatic drug, reduce tolerance 35 without affecting resistance. These include inhibitors of major stress response hubs such as 36 Hsp90, calcineurin, PKC1 and TOR. Accordingly, in an invertebrate infection model, adjuvant 37 combination therapy was significantly more effective than fluconazole alone in treating highly 38 tolerant isolates and did not improve the treatment of isolates with low tolerance levels.
49
Introduction radius (RAD) of the zone of inhibition, a parameter that relates to the MIC 65 , and the fraction of ( Supplementary Fig. 3e ). A series of strains derived from SC5314 by passaging were particularly sensitive to media differences, with lower RAD and higher FoG levels on rich 155 medium (YPD) than on casitone medium ( Supplementary Fig. 3f ), emphasizing that assays 156 must be performed under consistent conditions to ensure reproducible results. Importantly, area occupied by light pixels and the change in this area over time are proxies for colony size and growth rate, respectively 74 . Different C. albicans isolates exhibited different initial time of 181 colony appearance (ToA) on medium without drug ( Supplementary Fig. 4 ). At 10 µg/ml FLC, the 182 ToA was delayed relative to the drug-free condition (except for resistant strains such as T101, 183 Fig. 2e,f) . Notably, the ∆ToA (ToA on FLC -ToA without FLC) of high FoG isolates was shorter 184 than that of low FoG isolates (Fig. 2f ), and correlated with overall FoG levels (Fig. 2g ). This 185 suggests that high FoG strains overcome the inhibitory pressures of the antifungal more 186 efficiently than low FoG strains. Consistent with this, in liquid assays with drug, highly tolerant 187 isolates also displayed shorter lag times than related isolates with low tolerance levels 188 ( Supplementary Fig. 5a ).
189
A number of C. albicans growth parameters did not correlate with FoG levels. These 190 included cell viability in the presence of drug ( Fig. 2h ), consistent with FLC being fungistatic 191 rather than fungicidal. Unlike tolerant bacteria, which display reduced growth rates and longer 192 colony appearance times 2,75-77 , antifungal tolerance did not correlate with slower growth in three 193 sets of related C. albicans strains grown in liquid without drug, including: (1) passaged 194 derivatives of SC5314 with altered FoG levels, (2) a slow-growing clinical isolate (P37005) and 195 faster growing derivatives 78 and (3) a clb4 mutant 79 with delayed cell cycle progression relative fluoxetine, a serotonin inhibitor 21 ; and fluphenazine, an antipsychotic drug that stimulates ABC transporter expression and indirectly inhibits calcineurin via calmodulin 23, 28, 95 . FLC + adjuvant Persistent candidemia is associated with highly tolerant isolates. Echinocandins are considered the optimal line of therapy for patients with candidemia, yet FLC remains a frontline 284 drug for systemic C. albicans infections 103 , especially in low income countries 104 . Treatment with 285 FLC often fails despite isolates being drug-susceptible when tested in vitro, and rates of 286 persistent candidemia are often higher in patients treated with FLC rather than with 287 echinocandins 105,106 . To examine possible connections between susceptibility and tolerance 288 levels, we collected sets of clinical isolates from patients with candidemia that were either 289 efficiently cleared by a single course of FLC treatment (non-persistent) or that persisted in the 290 host despite extended FLC therapy ( Fig. 6a , Supplementary Fig. 10a , see detailed isolate 291 description in Methods).
292
The drug responses of persistent and non-persistent isolates and several control strains 293 displayed similar RAD and MIC levels (0.25-1 µg/ml), well below those of resistant strains 294 (clinical MIC breakpoint = 4 µg/ml), when assayed at both 24 and 48 h ( Fig. 6b and 295 Supplementary Fig. 10b ,c). Strikingly, FoG/SMG levels differed significantly between the two 296 groups of clinical isolates, especially when compared at 48 h (Fig. 6b ,c) and, as expected, 297 correlated well with one another ( Supplementary Fig. 10d , R 2 = 0.62). Importantly, persistent 298 candidemia isolates displayed higher FoG/SMG levels than those readily cleared upon FLC 299 treatment. In fact, many persistent isolates had FoG levels higher than 0.5, indicating that over 300 half of the cells in the population could grow, albeit slowly, in the presence of FLC ( Fig. 6b ).
301
Taken together, these experiments demonstrate that tolerance is an intrinsic property distinct 302 from drug susceptibility, and that tolerance levels correlate with infections that resist azole 303 treatment in the clinic.
305
Discussion designed to avoid the detection of tolerance 3,34 . Here, quantification and characterization of tolerance across C. albicans isolates found that many of them exhibit tolerance, defined as the quantifying tolerance revealed that it is: 1) a subpopulation effect and the size of the 314 subpopulation is stable; 2) due to slow growth in drug stress; 3) correlates with intracellular drug 315 levels; 4) dependent upon stress response pathways, and 5) mechanistically distinct from 316 resistance. Several adjuvants completely cleared FoG without altering susceptibility (MIC) and,
317
when combined with the fungistatic drug FLC, yielded a fungicidal cocktail. Consistent with this, 318 combination therapy was most effective in vivo at treating infections by high tolerance strains,
319
whereas the adjuvant did not improve FLC efficacy against low FoG isolates. Furthermore, C. 320 albicans isolates that cause persistent candidemia exhibited significantly higher tolerance than 321 isolates readily cleared by FLC. Thus, quantitatively measuring tolerance levels of infecting 322 isolates may provide important prognostic insights concerning both the success of FLC therapy 323 as well as the potential efficacy of combination therapies.
324
The subpopulation effect of tolerance is readily detected on agar plate assays, where 325 individual cells and their clonal progeny are evident; in liquid assays, cells become mixed and 326 subpopulation effects are more difficult to distinguish. Growth dynamics in colonies 74 , 327 microcolony formation 73 and liquid growth assays all suggest tolerance correlates with the 328 degree of growth after drug exposure. This implies that a subpopulation of cells is inherently 329 more able to adapt to drug than the rest of the population. Since the size of such subpopulations 330 appears stable, we suggest that tolerance is a function of cell physiology and environmental 331 responsiveness that differs between genetic backgrounds and growth conditions. the well-known role of efflux in drug resistance [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] . The factors other than uptake and efflux that impact intracellular FLC levels remain to be determined.
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Adjuvant drugs increase FLC cidality and efficacy via tolerance, not resistance. A novel 338 insight from this work is that inhibitors of cellular stress improve fluconazole efficacy, primarily 339 via their effect on tolerance and not resistance. This has two important implications. First, the 340 subpopulation nature of tolerance suggests that these stress pathways must exhibit cell-to-cell 341 variation. Second, the contributions of stress response pathways differ considerably between 342 isolates, albeit in a manner that maintains population heterogeneity (and the size of the tolerant 343 subpopulation) as a heritable feature of the given strain.
344
Tolerance is clearly related to the Hsp90-dependent response and distinct from bona 345 fide resistance. Hsp90 and calcineurin are well known to affect fungal drug responses,
346
including the cidality of azoles 19, 67, 87, 89, [119] [120] [121] [122] . How the TOR pathway, the unfolded protein 347 response, PKC signaling, sphingolipid synthesis, iron homeostasis, as well as fluoxetine and 348 fluphenazine affect drug responses and increase FLC cidality remains to be determined.
349
The distinction between resistance and tolerance is consistent with the mechanisms that 
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Virulence assays were performed with strain SC5314, with SC5314-derived isolates passaged 530 for 12 days in either YPD alone (2 'low' FoG isolates) or YPD plus 1 µg/ml FLC (4 'high' FoG 531 isolates), and with isolates NP03 and S12-01 from a clinical isolate set (see Supplementary 532 Table 1 ). Experiments were performed in duplicate (n = 24 larvae) and statistical differences 533 between larval groups were tested using the Mantel-Cox test. Negative controls included PBS,
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FLC alone or FLC + FNZ for groups of 24 larvae. No significant killing of larvae was observed 535 in either of these conditions. data in Fig. 2b , ALC provided clinical isolates and clinical input to the paper; AR, IVE, RJB and 
